Today we’re joined by a leader at the forefront of next-generation immunotherapy — Dr. Christian Leisner. Christian is the CEO and co-founder of CDR-Life, a biotechnology company pioneering a new class of highly targeted T-cell engaging therapies designed to tackle some of the most difficult-to-treat cancers.
With a PhD in Biochemistry from ETH Zurich and a Master’s in Molecular Biology and Chemistry from Roskilde University in Denmark, Christian has built a career that bridges deep scientific expertise with strategic leadership. Before launching CDR-Life, he held key roles at Novartis, Alcon, and the biotech success story ESBATech, contributing to global development programs across oncology, ophthalmology, autoimmunity, and cardiovascular disease.
Today, Christian leads CDR-Life’s mission to unlock the potential of MHC-targeted immunotherapies — developing treatments designed to precisely attack tumor cells by recognizing intracellular antigens, long thought to be ‘undruggable.’ Under his leadership, the company is shaping what could become a transformational approach in the fight against cancer.
We’re thrilled to have him with us today to explore the science, the strategy, and the future of immunotherapy
